Literature DB >> 8014289

Heparin clearance during continuous veno-venous haemofiltration.

M Singer1, T McNally, G Screaton, I Mackie, S Machin, S L Cohen.   

Abstract

OBJECTIVE: To determine whether premature clotting of haemofiltration circuits could be related to heparin removal across the filter membrane into the ultrafiltrate.
DESIGN: Randomised study using either unfractionated (n = 8) or low molecular weight (n = 7) heparin for anticoagulation of the haemofiltration circuit at 1000 and 600 U/h respectively. Samples were drawn at 1 and 2 h from arterial and venous limbs of the haemofilter circuit for measurement of plasma heparin (as anti-Factor Xa activity), antithrombin III and haematocrit. Ultrafiltrate samples were collected at the same time for measurement of anti-Xa activity.
SETTING: Intensive care unit. PATIENTS: Patients in acute renal failure requiring haemofiltration.
RESULTS: Both unfractionated and low molecular weight heparin plasma levels were within the range required for therapeutic anticoagulation in all but one patient at 2 h. Ultrafiltrate anti-Xa levels were insignificant. Antithrombin III levels in these critically ill patients were subnormal in 11 of the 15 studies.
CONCLUSIONS: Despite their small sizes, neither unfractionated nor low molecular weight heparins cross the haemofilter membrane into the ultrafiltrate in any measurable quantity. Both heparins were present in plasma at a level suitable for therapeutic anticoagulation. Subnormal levels of antithrombin III may be an important factor in determining filter longevity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8014289     DOI: 10.1007/bf01704703

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  8 in total

1.  Critical care algorithms. Management of continuous haemo(dia)filtration.

Authors:  R F Armstrong; C Bullen; S L Cohen; M Singer; A R Webb
Journal:  Clin Intensive Care       Date:  1990

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  Continuous arterial-venous hemodiafiltration in critically ill patients.

Authors:  H J Voerman; R J Strack van Schijndel; L G Thijs
Journal:  Crit Care Med       Date:  1990-09       Impact factor: 7.598

4.  Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies.

Authors:  C B Laurell
Journal:  Anal Biochem       Date:  1966-04       Impact factor: 3.365

5.  Plasma kallikrein-kinin system in patients with uncomplicated sepsis and septic shock--comparison with cardiogenic shock.

Authors:  F Martínez-Brotóns; J R Oncins; J Mestres; V Amargós; C Reynaldo
Journal:  Thromb Haemost       Date:  1987-08-04       Impact factor: 5.249

6.  Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4.

Authors:  D A Lane; J Denton; A M Flynn; L Thunberg; U Lindahl
Journal:  Biochem J       Date:  1984-03-15       Impact factor: 3.857

7.  Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemofiltration.

Authors:  J Schrader; W Stibbe; V W Armstrong; M Kandt; R Muche; H Köstering; D Seidel; F Scheler
Journal:  Kidney Int       Date:  1988-04       Impact factor: 10.612

Review 8.  Extracorporeal treatment of acute renal failure in the intensive care unit: a critical view.

Authors:  M Schetz; P M Lauwers; P Ferdinande
Journal:  Intensive Care Med       Date:  1989       Impact factor: 17.440

  8 in total
  8 in total

Review 1.  Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based?

Authors:  H M Oudemans-van Straaten; J P J Wester; A C J M de Pont; M R C Schetz
Journal:  Intensive Care Med       Date:  2006-02-02       Impact factor: 17.440

2.  Proximally delivered dilute heparin does not improve circuit life in continuous venovenous haemodiafiltration.

Authors:  G D Leslie; I G Jacobs; G M Clarke
Journal:  Intensive Care Med       Date:  1996-11       Impact factor: 17.440

3.  Antithrombin level and circuit thrombosis during hemofiltration after cardiopulmonary bypass.

Authors:  H Lanquetot; T Leprince; S Ragot; C Boinot; C Jayle; R Robert; L Macchi
Journal:  Intensive Care Med       Date:  2008-06-25       Impact factor: 17.440

4.  Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.

Authors:  Hiraku Tsujimoto; Yasushi Tsujimoto; Yukihiko Nakata; Tomoko Fujii; Sei Takahashi; Mai Akazawa; Yuki Kataoka
Journal:  Cochrane Database Syst Rev       Date:  2020-03-13

5.  Hemostasis during low molecular weight heparin anticoagulation for continuous venovenous hemofiltration: a randomized cross-over trial comparing two hemofiltration rates.

Authors:  Heleen M Oudemans-van Straaten; Muriel van Schilfgaarde; Pascal J Molenaar; Jos Pj Wester; Anja Leyte
Journal:  Crit Care       Date:  2009-12-03       Impact factor: 9.097

6.  Antithrombin supplementation for anticoagulation during continuous hemofiltration in critically ill patients with septic shock: a case-control study.

Authors:  Damien du Cheyron; Bruno Bouchet; Cédric Bruel; Cédric Daubin; Michel Ramakers; Pierre Charbonneau
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

7.  Efficacy of coupled plasma filtration adsorption (CPFA) in patients with septic shock: a multicenter randomised controlled clinical trial.

Authors:  Sergio Livigni; Guido Bertolini; Carlotta Rossi; Fiorenza Ferrari; Michele Giardino; Marco Pozzato; Giuseppe Remuzzi
Journal:  BMJ Open       Date:  2014-01-08       Impact factor: 2.692

8.  Heparin resistance in COVID-19 patients in the intensive care unit.

Authors:  D White; S MacDonald; T Bull; M Hayman; R de Monteverde-Robb; D Sapsford; A Lavinio; J Varley; A Johnston; M Besser; W Thomas
Journal:  J Thromb Thrombolysis       Date:  2020-08       Impact factor: 5.221

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.